Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo's Diabetes Combo May Find Home With General Practitioners

This article was originally published in The Pink Sheet Daily

Executive Summary

Despite FDA skepticism about fixed dosing, advisory committee says there are patients and providers who will benefit.

You may also be interested in...



Novo Nordisk, Sanofi Insulin Combo Products Clear US Regulatory Hurdles

US FDA approves Xultophy and Soliqua, both fixed-ratio combinations of a basal insulin and a GLP-1 agonist, on the same day even though Sanofi redeemed a priority review voucher that earned Soliqua an earlier user fee goal date.

Sanofi Loses iGlarLixi Advantage Over Novo's iDegLira Amid Pen Problems

FDA request for more information on pen injector forces three-month review extension, offsetting advantage from priority review voucher redemption.

US FDA Oncology, Device Centers Developing Public Diagnostic Standards

Pilot program would get around the ‘one drug, one test’ policy, which has created intellectual property issues.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel